DLL3 targeting chimeric antigen receptors and binding agents
US11673953B2 · kind B2 · utility
6Cited by
24References
31Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 27, 2020 |
| Grant date | Jun 13, 2023 |
| Priority date | — |
| Expiry date | Mar 7, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.